Nov 17, 2025 10:15 am EST Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections
Nov 5, 2025 4:20 pm EST SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 15, 2025 8:00 am EDT SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study
Sep 30, 2025 8:00 am EDT SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
Sep 4, 2025 8:30 am EDT SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
Aug 25, 2025 8:00 am EDT SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
Aug 13, 2025 4:30 pm EDT SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025 4:20 pm EDT SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
Apr 8, 2025 8:00 am EDT SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
